TSHA
Taysha Gene Therapies Inc
4.40$
+0.9%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | – | – | 100.0% | |
| 7.0% | 10.2% | 9.5% | 27.0% | – | -30.9% | – | 13.9% | – | 5.5% | – | – | – | |
| 93.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 94.5% | – | – | – | |
| 248.4% | 351.9% | 605.6% | 1,355.5% | 835.9% | 757.9% | 676.2% | 1,014.1% | – | 449.5% | – | – | 2,234.4% | |
| 181.0% | 186.4% | 207.7% | 659.9% | 441.9% | 327.8% | 354.4% | 432.9% | – | 161.0% | – | – | 709.8% | |
| 422.4% | 550.8% | 813.3% | 2,015.4% | 1,548.4% | 1,085.8% | 1,030.5% | 1,447.1% | – | 610.5% | – | – | 2,876.3% | |
| -329.4% | -450.8% | -713.3% | -1,915.4% | -1,448.4% | -985.8% | -930.5% | -1,347.1% | – | -516.0% | – | – | -2,792.3% | |
| 31.0% | 19.8% | 0.9% | 2.4% | 1.3% | 1.1% | 0.8% | 0.9% | – | 0.2% | – | – | 0.8% | |
| -2,467.1% | 1,324.7% | -705.4% | -1,882.0% | -1,427.5% | -929.0% | -935.2% | -1,353.6% | – | -507.8% | – | – | -2,728.0% | |
| -7.0% | -98.5% | 8.3% | – | – | -13.9% | – | – | – | – | – | – | – | |
| -2,467.1% | 1,324.7% | -705.4% | -1,882.0% | -1,427.5% | -929.0% | -935.2% | -1,353.6% | – | -507.8% | – | – | -2,728.0% | |
| -2,429.1% | 1,354.6% | -695.0% | -1,850.6% | -1,409.7% | -912.9% | -922.1% | -1,338.8% | – | -510.5% | – | – | -2,712.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.